Note 17 - Segments and Geographical Information

12 Months Ended

Dec. 31, 2024

Notes to Financial Statements

Segment Reporting Disclosure [Text Block]

17. Segments and Geographical Information

The Company’s chief operating decision maker is its Chief Executive Officer. The Company’s chief operating decision maker evaluates the operating results of the Company’s reportable segments based on cash used in operations, revenues and net income (loss).

We follow the accounting guidance of ASC 280, Segment Reporting (“ASC 280”). Reportable operating segments are determined based on the management approach. The management approach, as defined by ASC 280, is based on the way that the chief operating decision-maker organizes the segments within an enterprise for making operating decisions and assessing performance. While our results of operations are primarily reviewed on a consolidated basis, the chief operating decision-maker manages the enterprise in two reportable segments, each with different operating and potential revenue generating characteristics. 

The Company has two operating and reportable segments: i) Regenerative Biotech focused on the development of regenerative medicine treatments with operations currently in the United States and ii) Consumer Health Products relating to consumer health products with operations currently in Asia. All our revenue was generated in Asia. The following table represents selected financial information for our segments for the years ended December 31, 2024 and 2023, in thousands:

	Year Ended December 31,
	2024			2023
Product revenue:
Regenerative Biotech	$	—		$	—
Consumer Health Products		430			103
Total	$	430		$	103
Net loss:
Regenerative Biotech	$	(7,247	)	$	(8,677	)
Consumer Health Products		(485	)		(268	)
Total	$	(7,732	)	$	(8,945	)

	December 31,
	2024		2023
Cash and cash equivalents:
Regenerative Biotech	$	2,405	$	371
Consumer Health Products		81		61
Total	$	2,486	$	432
Total assets:
Regenerative Biotech	$	3,978	$	2,426
Consumer Health Products		464		188
Total	$	4,442	$	2,614